Brief: Clover Biopharmaceuticals Says Co's Covid-19 Vaccine Candidate Demonstrated Durable High Protection Against Omicron As Booster
17/03/2022 12:28
March 17 (Reuters) - Clover Biopharmaceuticals Ltd
2197.HK :
* CO'S COVID-19 VACCINE CANDIDATE DEMONSTRATED DURABLE HIGH
PROTECTION & STRONG IMMUNE RESPONSE AGAINST OMICRON AS BOOSTER
Further company coverage: 2197.HK
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune